JCM
AMAG

Julex Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Julex Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-28
Closed – – 190
2018
Q4 		$0 Buy
+28
New +$534 ﹤0.01% 126

Other funds holding AMAG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Julex Capital Management's AMAG Position: Q1 2019 in Review

Julex Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q1 2019, closing a stake of 28 shares.

Julex Capital Management first reported a position in AMAG in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 166 funds tracked by Wall St. Rank hold AMAG as of Q1 2019.

  • Julex Capital Management reported no remaining AMAG Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Julex Capital Management sold 28 AMAG Pharmaceuticals shares in Q1 2019.
  • Julex Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Julex Capital Management's AMAG Pharmaceuticals position peaked at $0 in Q4 2018.
  • 166 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2019.

Based on Julex Capital Management's 13F filing for Q1 2019, filed 15 May 2019.